A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab for Subjects with Advanced Solid Tumors

Type of Cancer
Unknown

Sponsor
Merck

Protocol Number
MK-1308-001

To Learn More Call
(201)-510-0950